Could a custom vaccine help fight ovarian cancer?
NCT ID NCT02111941
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a personalized vaccine made from a patient's own immune cells to see if it is safe for people with advanced ovarian, fallopian tube, or peritoneal cancer. Nineteen participants who had already undergone surgery and chemotherapy received the vaccine. The main goal was to check for serious side effects and to see if the vaccine could stimulate an immune response against cancer cells.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
personalized dendritic cell vaccine (loaded with folate receptor alpha peptides)
What this could lead to
If this vaccine proves safe and effective, it could offer a new way to help the immune system fight advanced ovarian cancer after standard treatments.
What could go wrong
This is a very early, small pilot study with only 19 participants. It primarily tests safety, not whether the vaccine actually controls the cancer. Many early-stage vaccines fail in larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN SEROMUCINOUS CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic
Rochester, Minnesota, 55905, United States